Limits...
Multilayered Graphene Nano-Film for Controlled Protein Delivery by Desired Electro-Stimuli.

Choi M, Kim KG, Heo J, Jeong H, Kim SY, Hong J - Sci Rep (2015)

Bottom Line: Taking full advantage of these versatile conducting sheets, we investigated the novel concept of applying graphene oxide (GO) and reduced graphene oxide (rGO) materials as both barrier and conducting layers that afford controlled entrapment and release of any molecules of interest.We fabricated multilayered nanofilm architectures using a hydrolytically degradable cationic poly(β-amino ester) (PAE), a model protein antigen, ovalbumin (OVA) as a building block along with the GO and rGO.This new drug delivery platform will find its usefulness in various transdermal drug delivery devices where on-demand control of drug release from the surface is necessary.

View Article: PubMed Central - PubMed

Affiliation: School of Chemical Engineering &Materials Science, Chung-Ang University, Seoul 156-756, Republic of Korea.

ABSTRACT
Recent research has highlighted the potential use of "smart" films, such as graphene sheets, that would allow for the controlled release of a variety of therapeutic drugs. Taking full advantage of these versatile conducting sheets, we investigated the novel concept of applying graphene oxide (GO) and reduced graphene oxide (rGO) materials as both barrier and conducting layers that afford controlled entrapment and release of any molecules of interest. We fabricated multilayered nanofilm architectures using a hydrolytically degradable cationic poly(β-amino ester) (PAE), a model protein antigen, ovalbumin (OVA) as a building block along with the GO and rGO. We successfully showed that these multilayer films are capable of blocking the initial burst release of OVA, and they can be triggered to precisely control the release upon the application of electrochemical potential. This new drug delivery platform will find its usefulness in various transdermal drug delivery devices where on-demand control of drug release from the surface is necessary.

No MeSH data available.


Related in: MedlinePlus

(A) Schematic illustration of the (PAE/rGO−/GO+/OVA/GO+/rGO−)40. (B) Representative surface morphology of a multilayer film: cross-sectional SEM image of as-assembled (PAE/rGO−/GO+/OVA/GO+/rGO−) 40-multilayer films. Scale bar = 100 nm. (C) Growth curve for electrostatically assembled (PAE/rGO−/GO+/OVA/GO+/rGO−)40 multilayer films versus the number of hexalayers.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4664934&req=5

f2: (A) Schematic illustration of the (PAE/rGO−/GO+/OVA/GO+/rGO−)40. (B) Representative surface morphology of a multilayer film: cross-sectional SEM image of as-assembled (PAE/rGO−/GO+/OVA/GO+/rGO−) 40-multilayer films. Scale bar = 100 nm. (C) Growth curve for electrostatically assembled (PAE/rGO−/GO+/OVA/GO+/rGO−)40 multilayer films versus the number of hexalayers.

Mentions: To fabricate an electro-responsive nanofilm capable of controlled ovalbumin (OVA) release, we engineered multilayer nanofilms with repeating hexalayer structures (PAE/rGO/GO/OVA/GO/rGO)n, n = number of hexalayer) by using poly(β-amino ester) (PAE), rGO, and GO as the building blocks (Fig. 2A). The major driving force for multilayer assembly is electrostatic interaction, where the adsorptions of the following occur in order onto the substrates: (i) positively charged PAE, (ii) GO and negatively charged OVA, and (iii) rGO39. The isoelectric point of OVA is 4.531. As such, OVA were negatively charged at the experimental pH of 6 and 7.4 at which our nanofilms were deposited and tested, respectively. Here, we utilized PAE as a component of our multilayer films due to their hydrolytic degradation characteristics that enables the release of drugs from the films38. Scanning electron microscopy reveals the morphology of (PAE/rGO/GO/OVA/GO/rGO)40; although the multilayers yielded some crease features, we found that they were uniformly coated without defect and exhibited layered morphology (Fig. 2B). Under physiological conditions, the thickness of the multilayer nanofilms increases linearly with the increasing number of hexalayers (n) as shown in Fig. 2C, indicating that precise control of film thickness (or OVA loading) can be achieved using the designed hexalayer structures.


Multilayered Graphene Nano-Film for Controlled Protein Delivery by Desired Electro-Stimuli.

Choi M, Kim KG, Heo J, Jeong H, Kim SY, Hong J - Sci Rep (2015)

(A) Schematic illustration of the (PAE/rGO−/GO+/OVA/GO+/rGO−)40. (B) Representative surface morphology of a multilayer film: cross-sectional SEM image of as-assembled (PAE/rGO−/GO+/OVA/GO+/rGO−) 40-multilayer films. Scale bar = 100 nm. (C) Growth curve for electrostatically assembled (PAE/rGO−/GO+/OVA/GO+/rGO−)40 multilayer films versus the number of hexalayers.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4664934&req=5

f2: (A) Schematic illustration of the (PAE/rGO−/GO+/OVA/GO+/rGO−)40. (B) Representative surface morphology of a multilayer film: cross-sectional SEM image of as-assembled (PAE/rGO−/GO+/OVA/GO+/rGO−) 40-multilayer films. Scale bar = 100 nm. (C) Growth curve for electrostatically assembled (PAE/rGO−/GO+/OVA/GO+/rGO−)40 multilayer films versus the number of hexalayers.
Mentions: To fabricate an electro-responsive nanofilm capable of controlled ovalbumin (OVA) release, we engineered multilayer nanofilms with repeating hexalayer structures (PAE/rGO/GO/OVA/GO/rGO)n, n = number of hexalayer) by using poly(β-amino ester) (PAE), rGO, and GO as the building blocks (Fig. 2A). The major driving force for multilayer assembly is electrostatic interaction, where the adsorptions of the following occur in order onto the substrates: (i) positively charged PAE, (ii) GO and negatively charged OVA, and (iii) rGO39. The isoelectric point of OVA is 4.531. As such, OVA were negatively charged at the experimental pH of 6 and 7.4 at which our nanofilms were deposited and tested, respectively. Here, we utilized PAE as a component of our multilayer films due to their hydrolytic degradation characteristics that enables the release of drugs from the films38. Scanning electron microscopy reveals the morphology of (PAE/rGO/GO/OVA/GO/rGO)40; although the multilayers yielded some crease features, we found that they were uniformly coated without defect and exhibited layered morphology (Fig. 2B). Under physiological conditions, the thickness of the multilayer nanofilms increases linearly with the increasing number of hexalayers (n) as shown in Fig. 2C, indicating that precise control of film thickness (or OVA loading) can be achieved using the designed hexalayer structures.

Bottom Line: Taking full advantage of these versatile conducting sheets, we investigated the novel concept of applying graphene oxide (GO) and reduced graphene oxide (rGO) materials as both barrier and conducting layers that afford controlled entrapment and release of any molecules of interest.We fabricated multilayered nanofilm architectures using a hydrolytically degradable cationic poly(β-amino ester) (PAE), a model protein antigen, ovalbumin (OVA) as a building block along with the GO and rGO.This new drug delivery platform will find its usefulness in various transdermal drug delivery devices where on-demand control of drug release from the surface is necessary.

View Article: PubMed Central - PubMed

Affiliation: School of Chemical Engineering &Materials Science, Chung-Ang University, Seoul 156-756, Republic of Korea.

ABSTRACT
Recent research has highlighted the potential use of "smart" films, such as graphene sheets, that would allow for the controlled release of a variety of therapeutic drugs. Taking full advantage of these versatile conducting sheets, we investigated the novel concept of applying graphene oxide (GO) and reduced graphene oxide (rGO) materials as both barrier and conducting layers that afford controlled entrapment and release of any molecules of interest. We fabricated multilayered nanofilm architectures using a hydrolytically degradable cationic poly(β-amino ester) (PAE), a model protein antigen, ovalbumin (OVA) as a building block along with the GO and rGO. We successfully showed that these multilayer films are capable of blocking the initial burst release of OVA, and they can be triggered to precisely control the release upon the application of electrochemical potential. This new drug delivery platform will find its usefulness in various transdermal drug delivery devices where on-demand control of drug release from the surface is necessary.

No MeSH data available.


Related in: MedlinePlus